Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The empirical choice of antibacterial agents in intra-abdominal infections requires consideration of a variety of factors

    • 42 Accesses

    This is a preview of subscription content, log in to check access.

    Table I

    References

    1. 1.

      Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs 2012; 72 (6): e17–32

    2. 2.

      Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000; 232 (2): 254–62

    3. 3.

      Ohlin B, Cederberg A, Forssell H, et al. Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intraabdominal infections. Eur J Surg 1999; 165 (9): 875–84

    4. 4.

      Walker AP, Nichols RL, Wilson RF, et al. Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 1993; 217 (2): 115–21

    5. 5.

      Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010 Jan 15; 50 (2): 133–64

    6. 6.

      Seguin P, Laviolle B, Chanavaz C, et al. Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 2006; 12 (10): 980–5

    7. 7.

      Montravers P, Lepape A, Dubreuil L, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009; 63 (4): 785–94

    8. 8.

      Augustin P, Kermarrec N, Muller-Serieys C, et al. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care 2010; 14 (1): R20

    9. 9.

      Cercenado E, Torroba L, Canton R, et al. Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis. J Clin Microbiol 2010; 48 (2): 456–9

    10. 10.

      Egea P, Lopez-Cerero L, Navarro MD, et al. Assessment of the presence of extended-spectrum beta-lactamase-producing Escherichia coli in eggshells and ready-to-eat products. Eur J Clin Microbiol Infect Dis 2011; 30 (9): 1045–7

    11. 11.

      Dolejska M, Matulova M, Kohoutova L, et al. Extended-spectrum beta-lactamase-producing Escherichia coli in turkey meat production farms in the Czech Republic: national survey reveals widespread isolates with bla(SHV-12) genes on IncFII plasmids. Lett Appl Microbiol 2011; 53 (3): 271–7

    12. 12.

      Jensen VF. The development of antibiotics use in Danish food production [in Danish]. Ugeskr Laeg 2011; 173 (45): 2862–6

    13. 13.

      Edelsberg J, Berger A, Schell S, et al. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt) 2008; 9: 335–47

    14. 14.

      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52 (4): e56–93

    15. 15.

      Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27 (6): 1066–72

    16. 16.

      Rex JH. Candida in the peritoneum: passenger or pathogen? Crit Care Med 2006; 34 (3): 902–3

    17. 17.

      Magill SS, Swoboda SM, Johnson EA, et al. The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. Diagn Microbiol Infect Dis 2006; 55 (4): 293–301

    18. 18.

      Agvald-Ohman C, Klingspor L, Hjelmqvist H, et al. Invasive candidiasis in long-term patients at a multidisciplinary intensive care unit: Candida colonization index, risk factors, treatment and outcome. Scand J Infect Dis 2008; 40 (2): 145–53

    19. 19.

      Blot S, Janssens R, Claeys G, et al. Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother 2006; 58 (2): 474–7

    20. 20.

      Laterre PF, Colardyn F, Delmée M, et al. Antimicrobial therapy for intra-abdominal infections: guidelines from the Infectious Disease Advisory Board (IDAB). Acta Chir Belg 2006 Jan–Feb; 106 (1): 2–21

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    The empirical choice of antibacterial agents in intra-abdominal infections requires consideration of a variety of factors. Drugs Ther Perspect 28, 13–16 (2012). https://doi.org/10.1007/BF03262121

    Download citation